134 related articles for article (PubMed ID: 37619265)
21. Synthesis and biological evaluation of theranostic Trastuzumab-SN38 conjugate for Near-IR fluorescence imaging and targeted therapy of HER2+ breast cancer.
Kobzev D; Prasad C; Walunj D; Gotman H; Semenova O; Bazylevich A; Patsenker L; Gellerman G
Eur J Med Chem; 2023 Apr; 252():115298. PubMed ID: 36966651
[TBL] [Abstract][Full Text] [Related]
22. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
24. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
25. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
26. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.
Tang Y; Tang F; Yang Y; Zhao L; Zhou H; Dong J; Huang W
Sci Rep; 2017 Aug; 7(1):7763. PubMed ID: 28798339
[TBL] [Abstract][Full Text] [Related]
27. Enabling the formation of native mAb, Fab' and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs).
Thoreau F; Rochet LNC; Baker JR; Chudasama V
Chem Sci; 2023 Apr; 14(14):3752-3762. PubMed ID: 37035695
[TBL] [Abstract][Full Text] [Related]
28. Development of HSP90 inhibitors-SN38 conjugates for cancer treatment.
Cao Y; Shen Q; Ding M; Chen Y; Lu W; Zhu S
Bioorg Chem; 2023 Aug; 137():106582. PubMed ID: 37156134
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy.
Yarian F; Alibakhshi A; Eyvazi S; Arezumand R; Ahangarzadeh S
J Cell Physiol; 2019 Aug; 234(10):16724-16738. PubMed ID: 30908646
[TBL] [Abstract][Full Text] [Related]
30. EGFR-targeted humanized single chain antibody fragment functionalized silica nanoparticles for precision therapy of cancer.
Wu H; Ding X; Chen Y; Cai Y; Yang Z; Jin J
Int J Biol Macromol; 2023 Dec; 253(Pt 8):127538. PubMed ID: 37866562
[TBL] [Abstract][Full Text] [Related]
31. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
[TBL] [Abstract][Full Text] [Related]
32. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
33. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
[TBL] [Abstract][Full Text] [Related]
34. Homogeneous Antibody-Drug Conjugates via Glycoengineering.
Tang F; Shi W; Huang W
Methods Mol Biol; 2019; 2033():221-238. PubMed ID: 31332757
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
Xie J; Zhang X; Teng M; Yu B; Yang S; Lee RJ; Teng L
Int J Nanomedicine; 2016; 11():1677-86. PubMed ID: 27217746
[TBL] [Abstract][Full Text] [Related]
36. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates.
Matsuda Y; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2021; 69(10):976-983. PubMed ID: 34602579
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
40. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]